← Back to screener

Atea Pharmaceuticals, Inc. AVIR

Rank #1614 · Nasdaq · $0.3B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
45.5
P/E
-2.0
P/B
0.59
ROE
-30.3%
Op. Margin
–%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -2.0x, P/B 0.59x. Ranks in the top 51% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -30.3%. Ranks in the top 84% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.0B$-0.0B$-0.0B-19.5-9
2021$0.0B$-0.0B$-0.0B$-0.0B-30.0-873
2022$0.0B$-0.0B$-0.0B$-0.0B-22.7-127
2023–$-0.1B$-0.1B$0.7B–4
2024–$-0.2B$-0.1B$0.6B–6
2025–$-0.2B$-0.2B$0.6B–5

← See the full screener